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Thrombus Aspiration During Primary
Percutaneous Coronary Intervention Improves
Myocardial Reperfusion and Reduces Infarct Size
The EXPIRA (Thrombectomy With Export Catheter
in Infarct-Related Artery During Primary Percutaneous
Coronary Intervention) Prospective, Randomized Trial
Gennaro Sardella, MD, FACC, FESC,* Massimo Mancone, MD,* Chiara Bucciarelli-Ducci, MD,*‡
Luciano Agati, MD,* Raffaele Scardala, MD,* Iacopo Carbone, MD,† Marco Francone, MD,†
Angelo Di Roma, MD,* Giulia Benedetti, MD,* Giulia Conti, MD,* Francesco Fedele, MD*
Rome, Italy; and London, United Kingdom
Objectives The purpose of this study was to evaluate the impact on myocardial perfusion and infarct size as assessed by
contrast-enhanced magnetic resonance imaging (CE-MRI) of a manual thrombectomy device, Export Medtronic
(EM) (Medtronic Inc., Minneapolis, Minnesota), as adjunctive therapy in primary percutaneous coronary interven-
tion (PPCI) in a subset of patients with anterior ST-segment elevation myocardial infarction (STEMI).
Background PPCI may cause thrombus dislodgment, leading to microvascular damage.
Methods One hundred seventy-five STEMI patients were randomly assigned to standard percutaneous coronary interven-
tion (PCI) (n  87) or EM-PCI (n  88). The primary end points were the occurrence of myocardial blush grade
2 and the rate of 90-min ST-segment resolution 70%. The CE-MRI substudy was performed in 75 patients
with anterior STEMI to assess microvascular obstruction and infarct size.
Results Myocardial blush grade 2 and ST-segment resolution occurred more frequently in the EM-PCI group (88%
vs. 60%, p  0.001; and 64% vs. 39%, p  0.001). In the acute phase, microvascular obstruction extent
was significantly lower in the EM-PCI group and at 3 months, infarct size was significantly reduced only in
the EM-PCI group. A lower incidence of cardiac death in the EM-PCI group (4.6% vs. 0%, log-rank test
p  0.02) was observed at 9 months.
Conclusions Thrombectomy prevents thrombus embolization and preserves microvascular integrity reducing infarct size, and
it therefore represents an useful adjunctive therapy in PPCI. (J Am Coll Cardiol 2009;53:309–15) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.017a
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Srimary percutaneous coronary intervention (PPCI) is the
tandard treatment in patients with ST-segment elevation
yocardial infarction (STEMI) achieving a Thrombolysis
n Myocardial Infarction (TIMI) flow grade 3 in 90% of
atients (1). However, despite a “brisk” epicardial coronary
ow in the infarct-related artery, microvascular damage
requently limits the efficacy of PPCI. Recent studies
uggest that thrombectomy improves myocardial perfusion
rom the Departments of *Cardiovascular, Respiratory and Morphologic Sciences and
Radiology Sciences, Policlinico “Umberto I,” “Sapienza” University, Rome, Italy;
nd the ‡Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital,
mperial College, National Heart and Lung Institute, London, United Kingdom.a
Manuscript received May 15, 2008; revised manuscript received September 12,
008, accepted October 7, 2008.nd reduces left ventricular (LV) remodeling by reducing
icrovascular damage (2–4). Contrast-enhanced magnetic
esonance imaging (CE-MRI) represents the gold-standard
echnique to identify and quantify microvascular obstruction
MVO) and infarct size (IS) (5,6) and to date, this imaging
echnique has not been applied to assess the efficacy of
hrombectomy. The aim of this trial was to evaluate the
mpact of a manual intracoronary aspiration thrombectomy
evice, Export Medtronic (EM) (Medtronic Inc., Minne-
polis, Minnesota), as adjunctive therapy for primary per-
utaneous coronary intervention (EM-PCI) on procedural
utcomes, myocardial blush grade (MBG) and 90-min
T-segment resolution (STr) 70%, and on MVO and IS
ssessed by CE-MRI in patients with anterior STEMI.
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Study population. One hun-
dred seventy-five consecutive pa-
tients admitted with STEMI and
candidates for PPCI were en-
rolled. Patients were randomly as-
signed in a 1:1 manner to EM-
PCI or standard percutaneous
coronary intervention (S-PCI). In
the CE-MRI substudy, a second
randomization (1:1) was per-
formed within anterior STEMI
patients only (Fig. 1).
The inclusion criteria were
as follows: first STEMI within
9 h from symptoms onset,
infarct-related artery 2.5 mm
in diameter, thrombus score
3, TIMI flow grade 1, and
age 18 years. Exclusion crite-
ria were a previous PCI on
infarct-related artery, previous
coronary artery bypass graft,
cardiogenic shock, 3-vessel dis-
ease, left main disease, severe
valvular heart disease, throm-
bolysis, and a contraindication
to glycoprotein IIb/IIIa inhibi-
tors administration.
tudy protocol and procedure. All patients were pre-
reated immediately before the revascularization with aspi-
Figure 1 Study Design
CE-MRI  contrast-enhanced magnetic resonance imaging; Contra  contraindicat
intervention; pt/pts  patient/patients; S  standard; STEMI  ST-segment eleva
thrombus score.
Abbreviations
and Acronyms
CE-MRI  contrast-
enhanced magnetic
resonance imaging
EM-PCI  Export Medtronic-
percutaneous coronary
intervention
IS  infarct size
LV  left ventricular
MACE  major adverse
cardiac events
MBG  myocardial blush
grade
MVO  microvascular
obstruction
PPCI  primary
percutaneous coronary
intervention
S-PCI  standard
percutaneous coronary
intervention
STEMI  ST-segment
elevation myocardial
infarction
STr  ST-segment
resolution
TIMI  Thrombolysis In
Myocardial Infarctionin 300 mg, intravenous heparin, abciximab at a standard
ose, and clopidogrel 300 mg. Thrombectomy was per-
ormed by more than 2 passages across the lesion. Subse-
uently, patients received aspirin, clopidogrel (12 months),
itrates, beta-blockers, angiotensin-converting enzyme in-
ibitors, and statins.
The protocol was accepted by the institutional ethical
oard, and was performed in accordance with the Declara-
ion of Helsinki. All patients provided written informed
onsent.
ngiographic and electrocardiography analysis. The
IMI flow grade and MBG were estimated visually by 2
xperienced observers, as previously described (7,8).
hrombus burden at the lesion site was graded from 0 to 5
ccording to the thrombus score (9). Interobserver and
ntraobserver coefficients of variation assessed in 20 ran-
omly selected patients were, respectively, 8% and 5% for
BG and 5% and 3% for TIMI. All patients underwent
2-lead electrocardiography at baseline and 90 min after
evascularization. The STr was measured as previously
escribed (10).
E-MRI acquisition protocol. Cardiac MRI was per-
ormed at days 3 to 5 after PPCI and at 3 months using a
.5-T scanner (Avanto-Siemens, Erlangen, Germany). Left
entricular function was assessed by standard steady-state
ree precession technique. Consecutive short-axis views
ere obtained by encompassing the left ventricle from base
o apex; vertical and horizontal long-axis views were ac-
uired. Typical image parameters were as follows: TE 1.6
s, TR  3.2 ms,   60°, matrix  256  256, slice
hickness 8 mm, gap 2 mm.
 Export Medtronic; GP  glycoprotein; PCI  percutaneous coronary
yocardial infarction; TIMI  Thrombolysis In Myocardial Infarction; TS ion; EM
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January 27, 2009:309–15 The EXPIRA TrialRest myocardial perfusion was evaluated with a first-
ass technique using a T1-weighted multishot gradient
cho echoplanar inversion-recovery sequence (TR  6.6
s, TE  1.3 ms, TI  240 ms, 25° flip angle, slice
hickness 10 mm). Three short-axis slices (basal, mid-
avity, and apical levels) were obtained injecting 0.1
mol/kg gadolinium-BOPTA (Multihance, Bracco, Mi-
an, Italy) at 2 ml/s followed by 20 ml saline flush in the
ight anterocubital vein. The CE-MRI images were
cquired in long- and short-axis views with a segmented
nversion-recovery fast gradient echo sequence 15 min
fter contrast injection. Sequence parameters were as
ollows: TR  600 ms, TE  3.8 ms,   25°, slice
hickness 8 mm, gap 2 mm. The inversion time was
rogressively optimized to null normal myocardium.
E-MRI analysis. All measurements were performed by 2
ully blinded operators using an off-line dedicated worksta-
ion (Siemens-Argus, Siemens AG, Erlangen, Germany).
eft ventricular ejection fraction, end-diastolic and -systolic
olumes, and LV mass were calculated from the short-
xis views.
The MVO and IS were quantified by manually drawing
he regions of hypointensity on the first-pass perfusion
mages and the regions of hyperintensity on the CE-MRI
hort-axis slices, respectively. The MVO was included in
he infarcted area. The MVO and IS are expressed in grams
assuming 1.05 g/ml as the specific gravity of the myocar-
ium) and as a percentage of the LV mass.
Interobserver and intraobserver coefficients of variation,
ssessed in 20 randomly selected patients, were 3% and 1%
or MVO and 3% and 2% for IS, respectively.
linical follow-up. Clinical follow-up was performed at 9
onths in all patients to assess the occurrence of the
ollowing major adverse cardiac events (MACE): cardiac
Baseline Clinical and Demographic Characterist
Table 1 Baseline Clinical and Demographic
Total
(n  175)
Age, yrs 65.3 11.2
Males (%) 105 (60.0)
Risk factors
Hypertension (%) 102 (58.3)
Diabetes (%) 37 (21.1)
Smoking (%) 66 (37.7)
Obesity (%) 7 (4.0)
Family history of CAD (%) 58 (33.1)
Cholesterol, mg/dl  SD 163 27
Triglycerides, mg/dl  SD 122 37
Renal failure (%) 14 (8.0)
Killip class III (%) 42 (24.0)
Symptoms to balloon, h  SD 6.1 1.3
LVEF, %  SD 41 13
ST-segment elevation, mV 22.9 13.5CAD  coronary artery disease; EM-PCI  Export Medtronic percutaneous co
standard percutaneous coronary intervention.eath, nonfatal reinfarction, and target vessel revasculariza-
ion. The incidence of stent thrombosis was also evaluated.
nd points. Primary study end points were the occurrence
f final MBG 2 and the rate of STr. End points of the
E-MRI substudy were the presence and extent of MVO
n the acute phase and IS extent at 3 months.
tatistical analysis. We estimated that 45 patients would
e required in each study group to have a power of 80% to
etect an absolute difference in the occurrence of MBG 2
f 30% with a 2-sided alpha value of 0.05. Categorical
ariables were analyzed by the chi-square or Fisher exact
est, as appropriate. All continuous variables were expressed
s mean  SD and analyzed by the Student t test.
vent-free survival curve for MACE was constructed using
he Kaplan-Meier method, and statistical differences be-
ween curves were assessed by the log-rank test. Statistical
nalysis was performed with StatView (version 5.0, SAS
nstitute, Cary, North Carolina).
esults
aseline characteristics. Two hundred fixty-six consecu-
ive STEMI patients were recruited, and 81 patients were
xcluded (Fig. 1). Clinical and angiographic characteristics
f EM-PCI and S-PCI are shown in Tables 1 and 2.
ngiographic and periprocedural findings. The EM-
CI showed a significant reduction of the thrombus burden
TS0-1: EM-PCI 63% vs. S-PCI 42%, p  0.006). The
ate of post-thrombectomy TIMI flow grade2 was higher
n EM-PCI (92% vs.77%, p  0.006), with a similar final
ate (EM-PCI 100% vs. S-PCI 98%, p  0.9) (Table 3).
rimary end points occurred more frequently in EM-PCI
MBG 2: 88% vs. 59%, p  0.0001; STr: 63% vs. 39%,
 0.001) (Table 3, Fig. 2).
linical outcomes. At 9 months, no differences were
bserved in terms of cumulative MACE (log-rank p 
f the Study Patients
acteristics of the Study Patients
S-PCI
(n  87)
EM-PCI
(n  88) p Value
64.6 12.5 66.7 14.1 0.298
48 (55.1) 57 (64.7) 0.218
43 (49.4) 59 (67.0) 0.021
16 (18.4) 21 (23.8) 0.459
23 (26.4) 43 (48.8) 0.003
2 (2.3) 5 (5.7) 0.443
32 (36.8) 26 (29.5) 0.338
167 15 161 11 0.002
125 26 124 31 0.817
7 (8.0) 7 (7.9) 1.00
25 (28.7) 17 (19.3) 0.160
6.1 1.8 6.2 0.9 0.642
40.7 9.3 42 10.5 0.192
22.3 9.3 23.6 10.5 0.384ics o
Charronary intervention; LVEF  left ventricular ejection fraction; S-PCI 
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The EXPIRA Trial January 27, 2009:309–15.14) (Fig. 2). However, S-PCI had a higher incidence of
ardiac death (log-rank p  0.02) than did EM-PCI (Fig. 3).
o stent thrombosis occurred in either group.
E-MRI evaluation. Seventy-five patients underwent car-
iac MRI (Fig. 4). One patient was excluded from the
nalysis owing to incomplete image acquisition (because of
laustrophobia), and 2 patients declined the follow-up scan
t 3 months.
No differences in the baseline ejection fraction, volumes,
nd IS were observed between the 2 groups. Post-
rocedural rate of MBG 2 and STr 70% was higher in
he EM-PCI group (89% vs. 59% and 84% vs. 40%,
espectively; p  0.0001). In the acute phase, greater
ncidence and extent of MVO was observed in the S-PCI
roup versus the EM-PCI group (72.9% vs. 31.5%, p 
Baseline Procedural Characteristics of the Stud
Table 2 Baseline Procedural Characteristics
Total
(n  175
Location of infarct-related artery (%)
LAD 76 (43.4
LCX 42 (24.0
RCA 57 (32.6
BARI score, % 28.9 10
Multivessel disease (%) 37 (26.8
Bifurcation (%) 23 (13.1
Lesion length, mm SD 14.5 5.
Vessel reference diameter, mm SD 2.9 0.
MLD before thrombectomy, mm SD 0.85 0.
Pre-thrombectomy thrombus score (%)
3 18 (10.3
4 62 (35.4
5 95 (54.3
BARI  Bypass Angioplasty Revascularization Investigation; LAD  le
lumen diameter; RCA  right coronary artery; other abbreviations as
Post-Procedural Angiographic Characteristics of
Table 3 Post-Procedural Angiographic Chara
Total
(n  175)
Procedure (%)
“Direct” stenting 69 (39.4)
Stent type (%)
Bare-metal stent 73 (41.7)
Drug-eluting stent 102 (58.3)
Post-stenting MLD, mm  SD 2.9 0.8
CK-MB peak, ng/ml 105 125
90-min ST-segment resolution (%) 90 (51.4)
ST-segment elevation, mV 10.2 15.3
Post-stenting TIMI flow grade (%)
2 174 (99.4)
0 to 1 1 (0.6)
Post-stenting MBG (%)
2 130 (74.3)
0–1 45 (25.7)CK-MB creatine kinase-myocardial band; MBGmyocardial blush grade; T
Tables 1 and 2..0005; and 3.7  2.6 g vs. 1.7  1.9 g, p  0.0003,
espectively); no differences were observed in IS (Table 4).
At 3 months, a reduction in final IS was detected in the
M-PCI group (IS mass from 17  15 g to 11  8.7 g,
 0.004; IS% from 14  12% to 9  4.5%, p  0.001),
hereas no changes were observed in the S-PCI group (Table
). MVO was not observed in either group at follow-up.
iscussion
n accordance with previous data (2–4), manual thrombec-
omy improves MBG and increases STr in selected STEMI
atients with angiographically visible thrombus. The
resent study showed a lower incidence and extent of MVO
fter recanalization and a reduced IS at 3 months for
ulation
e Study Population
S-PCI
(n  87)
EM-PCI
(n  88) p Value
38 (43.7) 38 (43.2) 1.00
20 (23.0) 22 (25.0) 0.859
29 (33.3) 28 (31.8) 0.872
28.1 9.2 29.7 6.1 0.17
16 (18.4) 21 (23.8) 0.459
11 (12.7) 12 (13.6) 1.00
14.4 6.6 14.7 3.9 0.714
2.9 0.5 2.9 0.6 1.00
0.86 0.2 0.83 0.3 0.438
9 (10.3) 9 (10.6) 1.00
32 (36.8) 30 (34.1) 0.753
47 (54.0) 48 (54.5) 1.00
rior descending artery; LCX  left circumflex artery; MLD  minimal
1.
Study Population
stics of the Study Population
S-PCI
(n  87)
EM-PCI
(n  88) p Value
2 (2.3) 67 (76.2) 0.0001
34 (39.1) 39 (44.3) 0.540
53 (60.9) 49 (55.7) 0.540
2.9 0.7 2.9 0.1 1.00
108 111 109 119 0.605
34 (39.1) 56 (63.6) 0.001
12.8 12.3 7.6 9.7 0.002
86 (98.9) 88 (100) 0.975
1 (1.1) 0 (0.0) 0.997
52 (59.8) 78 (88.6) 0.0001
35 (40.2) 10 (11.4) 0.0001y Pop
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January 27, 2009:309–15 The EXPIRA TrialM-PCI as compared with S-PCI. To our knowledge, this
s the first study evaluating the effects of thrombectomy on
VO and IS using CE-MRI.
CE-MRI is a noninvasive, high-resolution imaging
odality that identifies myocytes necrosis (IS) and mi-
rovascular damage (MVO), providing in vivo tissue
Figure 2 Kaplan-Meier 9-Month Cumulative Event-Free Survival
Kaplan-Meier analysis shows 9-month cumulative event-free survival of the standa
(S-PCI) treatment group as compared with the Export Medtronic percutaneous coro
Figure 3 Kaplan-Meier 9-Month Event-Free Survival for End Poin
Kaplan-Meier analysis shows 9-month event-free survival for the end point of death
intervention (S-PCI) treatment group as compared with the Export Medtronic percutharacterization in patients with myocardial infarction
5,6,11). Poor contrast penetration due to microvascular
amage reflects the complex pathophysiological mecha-
isms of no-reflow, from endothelial cell swelling and
ontracture to microvascular plugging and microemboli of
therosclerotic debris.
utaneous coronary intervention
tervention (EM-PCI) treatment group.
Death
e standard percutaneous coronary
s coronary intervention (EM-PCI) treatment group.rd perc
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The EXPIRA Trial January 27, 2009:309–15Mechanical thrombus removal followed by direct stenting
ay explain the better results obtained in EM-PCI. Con-
ersely, mechanical damage occurring during pre-dilation
ay explain the higher incidence and extent of MVO and
S detected in S-PCI.
Infarct shrinkage at 5 months was reported by Ing-
anisorn et al. (12) and Baks et al. (5) (34% and 31%
ecrease in IS, respectively). In our study, IS decreased at
months, by 35% in the EM-PCI group and by 7% in
he S-PCI group. In this latter group, impaired restora-
ion of normal blood flow may have led to inadequate scar
ealing. The smaller definitive IS may explain the lower
ncidence of MACE and the higher survival observed in
he EM-PCI group. Recently, the TAPAS (Thrombus
spiration During Percutaneous Coronary Intervention
n Acute Myocardial Infarction Study) trial showed a
urprisingly low rate of death in the thrombus aspiration
roup at 30 days and at 1-year follow-up (13). Improved
Figure 4 Cardiovascular MRI
(A to C, E to G) Short-axis rest perfusion images acquired at the apical, mid-cavit
(CE-MRI) scans with infarct planimetry. The patient in the standard percutaneous c
and mid-cavity slices (A and B, white arrows) that persists in the CE-MRI images
patient in the Export Medtronic percutaneous coronary intervention (EM-PCI) group
anterior infarction (planimetered area).
ardiac Magnetic Resonance Imaging Results
Table 4 Cardiac Magnetic Resonance Imaging Results
Acute Phase
S-PCI
(n  37)
EM-PCI
(n  38) p
EDV, ml 137.5 18.6 131.5 14.4 0
ESV, ml 77.4 15.4 71.3 17.3 0
EF, % 44.3 9.5 46.3 8.6* 0
IS, % 13 6.7 14 12† 0
IS, g 14 7.5 17 15‡ 0
MVO, n 27 (72.9%) 9 (31.5%) 0
MVO, g 3.7 2.6 1.7 1.9 0p  0.08. †p  0.001. ‡p  0.004.
EDV  end-diastolic volume; EF  ejection fraction; ESV  end-systolic volume; IS  infarction size; Myocardial reperfusion and higher infarct shrinkage
chieved by EM-PCI is likely related to a protective
ffect of thrombus aspiration on microvascular flow and
ight explain the significantly lower incidence of cardiac
eath in the EM-PCI group. These findings are valuable
n spite of the fact that the study was not powered to
ssess MACE.
In our cohort of patients, we did not observe significant
V remodeling at 3 months. In agreement with Galiuto
t al. (14), there was a trend toward higher increase in
nd-diastolic volumes with S-PCI. However, in our study
opulation, IS was relatively small; prompt revascularization
nd use of state-of-the-art pharmacological therapy could
artially account for this.
tudy limitations. This study represents a single-center
xperience with a limited number of patients. Assessing
VO only on the 3 short-axis rest perfusion slices (basal,
id, and apical) is likely to underestimate the size of MVO.
basal level. (D, H) Short-axis contrast-enhanced magnetic resonance imaging
ry intervention (S-PCI) group shows microvascular obstruction (MVO) in the apical
ck arrow) within the septal and anterior infarction (planimetered area). The
o MVO in the rest perfusion images (E to G). The CE-MRI image (H) shows an
3-Month Follow-Up
S-PCI
(n  36)
EM-PCI
(n  36) p Value
144.5 20.3 136.2 19.9 0.08
76.1 16.5 69.3 17.7 0.09
46.7 10.6 49.0 9.3* 0.3
11 8.7 9 4.5† 0.2
13 12 11 8.7‡ 0.4
— — —
— — —y, and
orona
(D, bla
has nValue
.1
.1
.3
.6
.2
.0005
.0003VO  microvascular obstruction; other abbreviations as in Table 1.
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January 27, 2009:309–15 The EXPIRA Trialome authors have recently observed the presence of MVO
n the delayed enhancement images (15). However, the
lassical definition of MVO by cardiac MRI is made on the
asis of the images acquired early after contrast injection,
ither first-pass imaging, as used in our study, or images
cquired 1 to 3 min after contrast injection (6). The MVO
epresents areas of poor contrast penetration, but these areas
sually fill in over time. Therefore, assessing MVO in the
ate images could also potentially underestimate the areas of
VO. In fact, in the time frame of 15 min (as opposed to
to 3 min), these areas of poor contrast penetration could
ll in with contrast. Both methods of first-pass perfusion
ith 3 representative short-axis slices or complete short-axis
tack acquired at 15 min after contrast injection present
ome advantages and limitations.
onclusions
anual aspiration thrombectomy preserves microvascular
ntegrity and reduces final IS after STEMI; thus, it may
epresent a useful adjunct to pharmacotherapy. Based on our
ndings, CE-MRI could provide a very useful tool for large
linical trials.
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